TECTONIC THERAPEUTIC, INC. (TECX) Current Ratio
- Current ratio · latest quarter: Value 22.29×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 22.29× | Current assets / current liabilities. $231.10M ÷ $10.37M ≈ 22.29× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 231.10M USD | Assets, Current |
| Current obligations | 10.37M USD | Liabilities, Current |
| Cash and equivalents | 227.07M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 1.68M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $231.10M | $10.37M | $227.07M | (m) | (m) | (m) | $1.68M | (m) | 22.29× |
| 2026-03-31 | $239.89M | $12.96M | $236.89M | (m) | (m) | (m) | $2.55M | (m) | 18.51× |
| 2025-12-31 | $257.36M | $9.67M | $253.80M | (m) | (m) | (m) | $1.09M | (m) | 26.63× |
| 2025-09-30 | $273.24M | $9.37M | $268.44M | (m) | (m) | (m) | $1.49M | (m) | 29.15× |
| 2025-06-30 | $290.85M | $11.36M | $287.38M | (m) | (m) | (m) | $2.80M | (m) | 25.60× |
| 2025-03-31 | $309.64M | $13.51M | $306.25M | (m) | (m) | (m) | $6.25M | (m) | 22.92× |
| 2024-12-31 | $146.86M | $11.61M | $141.24M | (m) | (m) | (m) | $976.00K | (m) | 12.65× |
| 2024-09-30 | $162.60M | $17.32M | $159.09M | (m) | (m) | (m) | $2.63M | (m) | 9.39× |
| 2024-06-30 | $187.39M | $26.00M | $185.12M | (m) | (m) | (m) | $4.09M | (m) | 7.21× |
| 2024-03-31 | $91.84M | $3.51M | $90.48M | (m) | (m) | (m) | $243.00K | (m) | 26.17× |
| 2023-12-31 | $30.88M | $40.89M | $28.77M | (m) | (m) | (m) | $409.00K | (m) | 0.76× |
| 2023-09-30 | $109.17M | $7.56M | $105.84M | (m) | (m) | (m) | $910.00K | (m) | 14.44× |
| 2023-06-30 | $128.84M | $11.66M | $124.69M | (m) | (m) | (m) | $1.07M | (m) | 11.05× |
| 2023-03-31 | $77.25M | $14.30M | $72.33M | (m) | (m) | (m) | $591.00K | (m) | 5.40× |
| 2022-12-31 | $99.96M | $13.12M | $92.56M | (m) | (m) | (m) | $384.00K | (m) | 7.62× |
| 2022-09-30 | $126.23M | $16.19M | $115.97M | (m) | (m) | (m) | $1.81M | (m) | 7.80× |
| 2022-06-30 | $142.08M | $12.79M | $132.41M | (m) | (m) | (m) | $28.00K | (m) | 11.11× |
| 2022-03-31 | $170.92M | $17.13M | $161.66M | (m) | (m) | (m) | $4.04M | (m) | 9.98× |
| 2021-12-31 | $199.15M | $19.39M | $189.57M | (m) | (m) | (m) | $3.49M | (m) | 10.27× |
| 2021-09-30 | $211.66M | $22.79M | $201.37M | (m) | (m) | (m) | $2.97M | (m) | 9.29× |
| 2021-06-30 | $233.52M | $16.95M | $226.44M | (m) | (m) | (m) | $2.03M | (m) | 13.77× |
| 2021-03-31 | $242.06M | $12.77M | $233.03M | (m) | (m) | (m) | $2.70M | (m) | 18.96× |
| 2020-12-31 | $267.24M | $16.61M | $259.68M | (m) | (m) | (m) | $2.68M | (m) | 16.09× |
| 2020-09-30 | $228.99M | $25.05M | $219.55M | (m) | (m) | (m) | $2.31M | (m) | 9.14× |
| 2020-06-30 | $251.02M | $15.41M | $244.38M | (m) | (m) | (m) | $2.62M | (m) | 16.29× |
| 2020-03-31 | $265.35M | $12.77M | $257.69M | (m) | (m) | (m) | $2.13M | (m) | 20.77× |
| 2019-12-31 | $195.70M | $14.02M | $187.04M | (m) | (m) | (m) | $3.95M | (m) | 13.96× |
| 2019-09-30 | $213.71M | $9.91M | $206.36M | (m) | (m) | (m) | $1.41M | (m) | 21.56× |
| 2019-06-30 | $98.19M | $8.77M | $90.35M | (m) | (m) | (m) | $2.57M | (m) | 11.20× |
| 2019-03-31 | $113.68M | $9.94M | $108.48M | (m) | (m) | (m) | $3.46M | (m) | 11.44× |
| 2018-12-31 | $130.02M | $10.61M | $126.30M | (m) | (m) | (m) | $2.78M | (m) | 12.26× |
| 2018-09-30 | $140.08M | $5.43M | $138.58M | (m) | (m) | (m) | $1.58M | (m) | 25.81× |
| 2018-06-30 | $156.15M | $9.63M | $155.01M | (m) | (m) | (m) | $4.19M | (m) | 16.21× |
| 2017-12-31 | $6.31M | $2.63M | $5.96M | (m) | (m) | (m) | $527.00K | (m) | 2.40× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |